AB0595 CURCUMA LONGA AND BOSWELLIA SERRATA FOR OSTEOARTHRITIS PAIN MANAGEMENT: A LITERATURE REVIEW OF SPECIFIC FORMULATED EXTRACTS FOR COMBINATION

Background: The need for safe, effective pain management osteoarthritis (OA) is important as the number of australian people with OA expected to grow by 30% from year 2015 2030. Extracts Boswellia serrata and Curcuma longa are described have anti-inflammatory analgesic properties. Clinical studies also reported efficacy improving joint stiffness tolerability. A combination formulated extracts might provide benefits in management. Objectives: To review literature describing efficacy, safety bioavailability a extract enriched boswellic acids piperine Methods: PubMed searches reporting safety, and/or data Curcumin formulations were conducted on 4 December 2020 no publication date limitations. Results: For formulation, two clinical assessing one preclinical study identified 1,2,3 . curcumin 2 4,5 Two double-blind, randomized, parallel, placebo-controlled (each N=60) demonstrated significant improvement Western Ontario McMaster Universities index (WOMAC) subscale scores patients knee receiving formulation (100mg/d): In first 1 , 30-day treatment Boswellia, compared placebo, significantly reduced WOMAC (−23.6; −5.6; P<0.0001) (−18.8; −3.4; P=0.0014) scores. Improvement visual analog scale (VAS) score was versus placebo at day 5 (P<0.05). second 90-day improved (−31.1; −8.4; (−27.7; −9.9; placebo; Of note, reduction functional ability observed early 7. curcumin/piperine added increase humans established comparative pharmacokinetic results obtained his demonstrates that enhances oral without side effects. Curcumin/piperine monotherapy (350-400mg TID) shown reduce WOMAC, VAS Lequesne’s (LPFI) randomized double-blind parallel-group (N=40) sub-study measured inflammatory biomarkers (N=40), there difference magnitude changes (IL-4, IL-6, hs-CRP, TNF-α, TGF-β mean ESR between curcuminoid group (p>0.05) 6 Conclusion: Enriched acid demonstrate suitable option: both ingredients, often cited natural alternatives address could be evaluated explore potential benefit combination. References: [1] Vishal et al. Int. J. Med. Sci. 2011, 8 [2] Sengupta 2010, 7 [3] Mol Cell Biochem. 354:189-197. [4] Shoba Planta 1998 May;64(4):353-6 [5] Panahi Phytother. Res. 28: 1625–1631 (2014). [6] Rahimnia A-R Drug Res 2015; 65: 521–525. Disclosure Interests: Vidhu Sethi Employee of: GSK Consumer Healthcare, Kamran Siddiqui Manohar Garg: None declared.